serw-MX  [xml]  

 DeCS Categories

A08 Nervous System .
A08.186 Central Nervous System .
C10 Nervous System Diseases .
C10.228 Central Nervous System Diseases .
C10.228.140 Brain Diseases .
C10.228.140.163 Brain Diseases, Metabolic .
C10. Brain Diseases, Metabolic, Inborn .
C10. Lysosomal Storage Diseases, Nervous System .
C16 Congenital, Hereditary, and Neonatal Diseases and Abnormalities .
C16.320 Genetic Diseases, Inborn .
C16.320.565 Metabolism, Inborn Errors .
C16.320.565.189 Brain Diseases, Metabolic, Inborn .
C16.320.565.189.435 Lysosomal Storage Diseases, Nervous System .
C16.320.565.595 Lysosomal Storage Diseases .
C16.320.565.595.554 Lysosomal Storage Diseases, Nervous System .
C18 Nutritional and Metabolic Diseases .
C18.452 Metabolic Diseases .
C18.452.132 Brain Diseases, Metabolic .
C18.452.132.100 Brain Diseases, Metabolic, Inborn .
C18.452.132.100.435 Lysosomal Storage Diseases, Nervous System .
C18.452.648 Metabolism, Inborn Errors .
C18.452.648.189 Brain Diseases, Metabolic, Inborn .
C18.452.648.189.435 Lysosomal Storage Diseases, Nervous System .
C18.452.648.595 Lysosomal Storage Diseases .
C18.452.648.595.554 Lysosomal Storage Diseases, Nervous System .
D01 Inorganic Chemicals .
D01.045 Alkalies .
D01.045.125 Carbonates .
D01.045.125.500 Lithium Carbonate .
D01.200 Carbon Compounds, Inorganic .
D01.200.275 Carbonic Acid .
D01.200.275.150 Carbonates .
D01. Lithium Carbonate .
D01.268 Elements .
D01.268.549 Metals, Alkali .
D01.268.549.450 Lithium .
D01.268.557 Metals, Light .
D01.268.557.290 Lithium .
D01.510 Lithium Compounds .
D01.510.475 Lithium Carbonate .
D01.552 Metals .
D01.552.528 Metals, Alkali .
D01.552.528.480 Lithium .
D01.552.547 Metals, Light .
D01.552.547.290 Lithium .
D12 Amino Acids, Peptides, and Proteins .
D12.776 Proteins .
D12.776.157 Carrier Proteins .
D12.776.157.530 Membrane Transport Proteins .
D12.776.157.530.200 Amino Acid Transport Systems .
D12.776.157.530.200.500 Amino Acid Transport Systems, Neutral .
D12.776.157.530.200.500.100 Amino Acid Transport System A .
D12.776.543 Membrane Proteins .
D12.776.543.585 Membrane Transport Proteins .
D12.776.543.585.200 Amino Acid Transport Systems .
D12.776.543.585.200.500 Amino Acid Transport Systems, Neutral .
D12.776.543.585.200.500.100 Amino Acid Transport System A .
D27 Chemical Actions and Uses .
D27.505 Pharmacologic Actions .
D27.505.954 Therapeutic Uses .
D27.505.954.427 Central Nervous System Agents .
N03 Health Care Economics and Organizations .
N03.540 Organizations .
N03.540.452 Health Planning Organizations .
N03.540.452.508 State Health Planning and Development Agencies .
N03.540.452.508.440 Health Systems Agencies .
SH1 Health Sciences, Technology and Innovation Management .
SH1.010 Policies and Cooperation in Science, Technology and Innovation .
SH1.010.020 International Cooperation .
SH1.010.020.080 Health Planning Organizations .
SH1. Health Systems Agencies .
SP4 Environmental Health .
SP4.011 Science .
SP4.011.097 Chemistry .
SP4.011.097.063 Elements .
SP4. Lithium .
 Synonyms & Historicals
Lithium Carbonate .
CP-15,467-61 .
Dilithium Carbonate .
Eskalith .
Lithane .
Lithium Bicarbonate .
Lithobid .
Lithonate .
Lithotabs .
Micalith .
NSC-16895 .
Priadel .
Quilinorm-retard .
Bicarbonate, Lithium .
CP 15,467 61 .
CP15,46761 .
Carbonate, Dilithium .
Carbonate, Lithium .
NSC 16895 .
NSC16895 .
Quilinorm retard .
Quilinormretard .
A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems. .
Lithium .
Lithium-7 .
Lithium 7 .
An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER. .
Central Nervous System Agents .
Central Nervous System Drugs .
A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252) .
Central Nervous System .
Cerebrospinal Axis .
Axi, Cerebrospinal .
Axis, Cerebrospinal .
Central Nervous Systems .
Cerebrospinal Axi .
Nervous System, Central .
Nervous Systems, Central .
System, Central Nervous .
Systems, Central Nervous .
The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges. .
Lysosomal Storage Diseases, Nervous System .
Lysosomal Enzyme Disorders, Nervous System .
Nervous System Lysosomal Enzyme Disorders .
Nervous System Lysosomal Storage Diseases .
A group of enzymatic disorders affecting the nervous system and to a variable degree the skeletal system, lymphoreticular system, and other organs. The conditions are marked by an abnormal accumulation of catabolic material within lysosomes. .
Amino Acid Transport System A .
Amino Acid Transport System A Proteins .
Amino Acid Transporter A .
System A Transporter .
System A Transporter Proteins .
Transporter, System A .
A sodium-dependent neutral amino acid transporter that accounts for most of the sodium-dependent neutral amino acid uptake by mammalian cells. The preferred substrates for this transporter system include ALANINE; SERINE; and GLUTAMINE. .
Health Systems Agencies .
Agencies, Health Systems .
Agency, Health Systems .
Health Systems Agency .
Systems Agencies, Health .
Systems Agency, Health .
Comprehensive Health Planning Agencies .
Health planning and resources development agencies which function in each health service area of the United States (PL 93-641). .